Showing 1 - 10 of 13 Eric Bernicker

Status: Open Not Enrolling

Investigator: Eric Bernicker

Study Coordinator: Daniel (cancer) Le (cancer)

Phone: 346.238.5655

Keynote 695 will be a Phase 2 study of intratumoral tavokinogene telseplasmid (tavo; pIL-12) Electroporation (EP) plus IV Pembrolizumab. Eligible patients will be those with pathological diagnosis of unresectable or metastatic melanoma who are p ... Read more >

Status: Enrolling

Investigator: Eric Bernicker

Study Coordinator: Elizabeth Soriano

Phone: 713.441.14203

To evaluate the overall survival of HLA-A*0201 positive adult patients with previously untreated advanced UM receiving IMCgp100 compared to Investigator's Choice of dacarbazine, ipilimumab, or pembrolizumab. ... Read more >

Status: Enrolling

Investigator: Eric Bernicker

Study Coordinator: Daniel (cancer) Le (cancer)

Phone: 346.238.5655

This randomized phase III trial studies how well crizotinib works and compares it to placebo in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called ALK. Mutation ... Read more >

Status: Open Not Enrolling

Investigator: Eric Bernicker

Study Coordinator:

Phone:

This is a Phase III, global, multicenter, open-label, randomized study to compare the efficacy and safety of 16 cycles (1 cycle duration=21 days) of atezolizumab (MPDL3280A) treatment compared with best supportive care (BSC) in participants with ... Read more >

Status: Enrolling

Investigator: Eric Bernicker

Study Coordinator: Juan Morales Viera

Phone: 786.803.2333

Major pathological response (MPR) rate of canakinumab given as a neoadjuvant treatment, either as single agent or in combination with pembrolizumab, in addition to evaluate the MPR rate of pembrolizumab as a single agent. Additionally the dynami ... Read more >

Status: Open Not Enrolling

Investigator: Eric Bernicker

Study Coordinator: Juan Morales Viera

Phone: 786.803.2333

This randomized, open-label study will evaluate the safety and efficacy of atezolizumab (an engineered anti-programmed death-ligand 1 [PD-L1] antibody) in combination with carboplatin+paclitaxel with or without bevacizumab compared with treatmen ... Read more >

Status: Open Not Enrolling

Investigator: Eric Bernicker

Study Coordinator:

Phone:

This randomized phase II trial studies how well pazopanib hydrochloride works in treating patients with carcinoid tumors that are growing, spreading, or getting worse. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some o ... Read more >

Status: Enrolling

Investigator: Eric Bernicker

Study Coordinator: Daniel (cancer) Le (cancer)

Phone: 346.238.5655

This research trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment ... Read more >

Status: Open Not Enrolling

Investigator: Eric Bernicker

Study Coordinator: Toniva Boone

Phone: 713.441.0686

This randomized phase III trial studies how well nivolumab after surgery and chemotherapy work in treating patients with stage IB-IIIA non-small cell lung cancer. Monoclonal antibodies, such as nivolumab, may stimulate the immune system in diffe ... Read more >

Status: Enrolling

Investigator: Eric Bernicker

Study Coordinator:

Phone:

This study is designed to identify the target Non-Small Cell Lung Cancer (NSCLC) population(s) that over express c-Met (c-Met+) best suited for telisotuzumab vedotin therapy in the second line or third line setting (Stage 1) and then to expand t ... Read more >

Status: Open Not Enrolling

Investigator: Eric Bernicker

Study Coordinator: Lacey Burey

Phone: 713.441.1159

The purpose of this pilot study is to characterize the composition/diversity of the gut microbiome in patients with metastatic NSCLC who are receiving standard of care checkpoint blockade immunotherapy. This study will lay the groundwork for lar ... Read more >

Status: Open Not Enrolling

Investigator: Eric Bernicker

Study Coordinator: Erick Villarreal-Williams

Phone: 346.238.5594

This randomized phase III trial studies how well erlotinib hydrochloride compared to placebo works in treating patients with stage IB-IIIA non-small cell lung cancer that has been completely removed by surgery. Erlotinib hydrochloride may stop t ... Read more >

Status: Open Not Enrolling

Investigator: Eric Bernicker

Study Coordinator:

Phone:

Cancer patients have an almost unique risk profile in this pandemic. Many patients, especially those actively on treatment, have high levels of contact with the healthcare system. Many if not all cancer patients are immunocompromised, through th ... Read more >